The purpose of the study is to determine if niraparib can help patients live longer without the disease getting worse, compared to temozolomide. Participants in the study will be randomly assigned to receive either niraparib or temozolomide. The study will monitor the participants over time to see how the treatments affect their health and the progression of their glioblastoma.

Throughout the study, researchers will also look at how the treatments impact overall survival, which means the length of time patients live after starting the treatment. Additionally, the study will assess the participants’ symptoms, quality of life, and any side effects they may experience. This information will help determine the safety and effectiveness of niraparib compared to temozolomide for treating this specific type of glioblastoma.

Patients taking part in this study will have already completed an initial phase of treatment that combined radiation therapy with temozolomide. After joining the study, they will receive the experimental vaccine UCPVax as an injection, and depending on which treatment group they are in, they may also receive pembrolizumab as an infusion. These treatments will be given alongside the standard maintenance therapy with temozolomide. The study will track patients for several years to measure how well the treatments work and to monitor any side effects that may occur.

During the study, doctors will regularly check how patients are doing through medical examinations, blood tests, and brain scans. They will also assess the quality of life of patients using questionnaires. The study will look at whether the cancer grows or spreads and will measure how long patients live after starting the treatment. Safety will be carefully monitored throughout the study by tracking any unwanted effects from the medications and checking routine laboratory results.

The study has multiple parts. In the first part, researchers will determine the safest and most effective dose of the combination treatment. In the second part, some patients will receive both medications while others will receive only lomustine. The treatment involves regular doses of lomustine, while 131I-TLX101 is given through an intravenous injection. The study will track how patients respond to the treatment and monitor any side effects that may occur.

Before joining the study, patients must undergo special imaging called FET PET scan to confirm their tumor status. This scan uses a special substance that helps doctors see if the treatment might be suitable for the patient. Throughout the study, patients will have regular check-ups, including blood tests, physical examinations, and quality of life assessments to monitor their health and response to treatment.

The purpose of the study is to investigate the safety and feasibility of using this treatment method in patients aged 18 to 75 who have been diagnosed with grade IV glioblastoma. Participants will receive the treatment during surgery, and the study will monitor how well the treatment is tolerated and determine the best light dose to use in future trials. The study will also look at how long it takes for the disease to progress after the treatment and gather feedback on the usability of the device used in the procedure.

Throughout the study, participants will be closely monitored for any side effects or adverse events. The study aims to provide valuable information on the potential benefits and risks of using Pentalafen and Heliance in treating glioblastoma, which could lead to improved treatment options for patients with this challenging condition.

The study will involve two groups of participants. The first group will include healthy individuals to help determine the right amount of iron oxide needed for clear brain imaging. The second group will consist of patients with glioblastoma. These patients will undergo MRI scans using a new imaging protocol to see how well the iron oxide highlights the tumor and its spread. The study aims to improve the understanding of glioblastoma behavior and enhance imaging techniques to better monitor the disease.

The trial is expected to start recruiting participants in early 2025 and will continue until early 2027. The findings from this study could provide valuable insights into the treatment and monitoring of glioblastoma, potentially leading to better outcomes for patients with this challenging condition.

The purpose of the study is to compare the overall survival of patients receiving the combination of Optune, temozolomide, and pembrolizumab with those receiving Optune, temozolomide, and a placebo. Participants will be randomly assigned to one of these two groups. The study will be conducted over a period of time, with regular monitoring and assessments to track the progress and effects of the treatment. The trial aims to provide valuable information on whether the addition of pembrolizumab to the existing treatment can improve survival rates for patients with newly diagnosed glioblastoma.

Throughout the study, participants will undergo various evaluations to ensure their safety and to gather data on the treatment’s effectiveness. The trial will help determine if this combination of treatments can offer a better outcome for patients facing this aggressive form of brain cancer. The study is expected to continue until 2028, with the goal of advancing the understanding and management of glioblastoma.

Participants in the study will receive either the standard treatment for glioblastoma or the standard treatment plus Zometa. The study will monitor how long patients live and how long they remain free from disease progression. The study will also look at the safety and any side effects of the treatment. The trial is designed to be open-label, meaning both the doctors and the participants will know which treatment is being given.

The study will take place over several years, with regular check-ups to assess the health and progress of the participants. The trial aims to provide valuable information on whether adding zoledronic acid to the standard therapy can offer better outcomes for patients with glioblastoma. Participants will be closely monitored for any adverse effects to ensure their safety throughout the study.

The purpose of this study is to find out the highest dose of itraconazole that can be safely given to patients with newly diagnosed GBM while they are also receiving RT and TMZ. This is known as determining the maximum tolerated dose. Participants in the study will take itraconazole in the form of hard capsules by mouth. The study will monitor how well patients tolerate the combination of these treatments over a period of time.

Throughout the study, patients will receive regular check-ups and imaging tests like MRI to track the progress of their treatment. The study aims to gather important information that could help improve treatment options for people diagnosed with GBM in the future.

Participants in the study will receive metformin in addition to their regular cancer treatment. The study will monitor the progress of the disease over a period of six months using MRI scans, which are imaging tests that help doctors see inside the body. The goal is to determine if metformin can help slow down the progression of the cancer. The study will also look at the quality of life of the participants and monitor any side effects they may experience.

Throughout the study, researchers will collect various health data, including blood tests to check for any changes in liver and kidney function, as well as blood sugar levels. The study will also involve analyzing tissue samples taken during surgery to understand how the cancer cells respond to the treatment. This research is expected to provide valuable insights into the potential benefits of metformin for patients with glioblastoma.

Participants in the study will receive doxorubicin through an intravenous infusion, which means it will be administered directly into a vein. Temozolomide will be taken orally, meaning it is swallowed in pill form. The study will observe how well patients tolerate this combination of treatments after they have undergone radiotherapy, which is a type of cancer treatment that uses high doses of radiation to kill cancer cells and shrink tumors.

The purpose of the study is to gather information on how safe and effective this treatment approach is for young patients with glioblastoma. The study will monitor participants over a period of time to see how they respond to the treatment and to identify any side effects that may occur. This information will help doctors understand if this combination of treatments can be a viable option for treating glioblastoma in pediatric and young adult patients.

The purpose of the study is to find the best dose of AGuIX when used with radiotherapy and Temozolomide, and to see how effective this combination is in treating glioblastoma. The study is divided into two phases. In the first phase, researchers will determine the safest and most effective dose of AGuIX. In the second phase, they will evaluate how well the treatment works by looking at how long patients live without the cancer getting worse over a period of six months. Some participants will receive a placebo instead of AGuIX to compare the results.

Participants in the study will receive the treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will also monitor the overall survival of participants, their response to the treatment, and any side effects they may experience. Additionally, the study will assess the distribution of the nanoparticles in the body and their impact on the tumor environment. The trial is expected to continue until 2027, with ongoing assessments to ensure the safety and effectiveness of the treatment.

The treatment being studied includes the use of temozolomide, a chemotherapy drug, and may also involve lomustine, another chemotherapy medication. Additionally, a special gas called perflutren is used to help with the ultrasound process. Some patients will receive a placebo instead of the ultrasound treatment to help researchers understand the true effects of the ultrasound. The purpose of the study is to determine if the ultrasound method can improve the time patients live without the disease getting worse, known as progression-free survival.

Participants in the study will undergo a series of treatments and assessments over a period of time. This includes regular check-ups and imaging tests like MRI to monitor the tumor’s response to the treatment. The study aims to provide valuable information on whether this new approach can offer better outcomes for patients with newly diagnosed glioblastoma. The trial will continue until enough data is collected to make a clear comparison between the different treatment methods.

The purpose of the study is to evaluate the safety and effectiveness of combining these two treatments. The study is divided into two phases. In the first phase, the focus is on assessing the safety and tolerability of the treatment combination. In the second phase, the study aims to determine if the combination of treatments can improve the overall survival of patients compared to using radiation therapy alone. Participants will receive the treatments and be monitored over time to see how they respond.

Throughout the study, participants will undergo regular check-ups and tests, including MRI scans, to track the progress of their disease and any side effects from the treatments. The study will also look at how the treatments affect the quality of life and cognitive functions of the participants. The trial is expected to continue until 2026, with ongoing assessments to gather comprehensive data on the treatment’s impact on recurrent glioblastoma.

The standard treatment for glioblastoma includes surgery to remove as much of the tumor as possible, followed by radiotherapy and chemotherapy with a drug called temozolomide. In this study, patients will receive the GlioVax vaccine in addition to these standard treatments. The vaccine is given intradermally, which means it is injected into the skin. The study will monitor patients over a period of time to assess their overall survival and any potential side effects from the vaccine.

Participants in the study will be closely observed to determine how well they respond to the treatment and to ensure their safety. The study will also evaluate the quality of life and neurological performance of the patients using various assessments. The goal is to find out if the vaccine can improve outcomes for patients with glioblastoma when used alongside the usual care. The study is expected to continue until 2027, providing valuable insights into the potential benefits of this new treatment approach.

The purpose of the study is to determine the best dose of the vaccine and to see how well it works in stimulating the immune system. The study will be conducted in two phases. In the first phase, researchers will find the maximum dose that patients can tolerate. In the second phase, they will assess how the immune system responds to the vaccine after two months. Participants will receive the vaccine through injections under the skin, and their health will be monitored regularly through clinical check-ups, blood tests, and MRI scans to ensure safety and effectiveness.

Throughout the study, researchers will evaluate the immune response by measuring specific cells in the blood that are known to fight cancer. They will also monitor the participants’ overall health, quality of life, and survival rates. The study aims to provide valuable insights into the potential benefits of this new vaccine approach for treating glioblastoma.

Participants in the study will take the medication orally over a period of time, and their progress will be monitored through various medical imaging techniques, such as MRI (Magnetic Resonance Imaging). These imaging techniques help in assessing changes in blood flow and the physical stress within the tumors. The study aims to observe how the tumors respond to the medication over time, with regular check-ups and imaging sessions scheduled throughout the study period.

The study will also track changes in the participants’ neurological performance and quality of life, using established scoring systems like the Karnofsky Performance Score (KPS) and the Eastern Cooperative Oncology Group (ECOG) scores. Additionally, the study will monitor the overall survival rates and any side effects experienced by participants during the treatment. The trial is expected to continue until the end of 2025, providing valuable insights into the potential benefits of losartan for patients with these specific brain tumors.

The purpose of the study is to evaluate how effective this new treatment is in helping patients with glioblastoma live longer without their disease getting worse. Participants in the study will receive the treatment as an injection under the skin, known as an intradermal injection. The study will compare the effects of this treatment with those of standard therapy, which typically includes a combination of radiation and chemotherapy. Some participants may receive a placebo instead of the new treatment to help researchers understand its true effects.

Throughout the study, participants will undergo regular assessments, including MRI scans, to monitor the size and progression of their tumors. These assessments will help determine how well the treatment is working. The study aims to provide valuable information on whether this new immune therapy can improve outcomes for patients with glioblastoma.

The purpose of the study is to evaluate how safe and tolerable this new treatment is for patients. Participants will receive the treatment in the form of an oral solution, which means it is taken by mouth. The study will monitor patients for any side effects or adverse reactions for a period of 28 days after the treatment is administered. This monitoring will include regular check-ups and tests to ensure the safety of the participants.

Throughout the study, changes in the tumor will be observed using MRI scans, which are imaging tests that help doctors see inside the body. The study will also look at how the treatment affects the tumor at a cellular level. This trial aims to provide valuable information about the potential of 5-ALA combined with SDT as a treatment option for high-grade glioma.

The purpose of the study is to see if adding this vaccine to the standard treatment with temozolomide can help patients live longer and prevent the cancer from getting worse. Patients who have recently been diagnosed with glioblastoma and have undergone surgery to remove the tumor, followed by a combination of chemotherapy and radiation, are eligible to participate. The study will involve regular injections of the vaccine, along with continued treatment with temozolomide, to see how well this combination works.

Participants in the study will receive either the vaccine or a placebo, in addition to temozolomide, and will be monitored over time to assess their health and response to the treatment. The study aims to gather information on the safety and effectiveness of this new treatment approach, with the hope of improving outcomes for patients with glioblastoma.

The purpose of this study is to determine the safest and most effective ultrasound power level that can be used with the SonoCloud-9 device to temporarily open the blood-brain barrier. This opening allows the chemotherapy medication to better reach the tumor. The blood-brain barrier is a natural protective layer that normally prevents many substances, including medications, from entering the brain tissue.

During the study, participants will have the SonoCloud-9 device surgically implanted. They will receive regular treatments where ultrasound is used to open the blood-brain barrier, followed by chemotherapy with carboplatin. The treatment will be repeated in cycles, and doctors will closely monitor how well patients tolerate the procedure and watch for any side effects that may occur.

The purpose of the study is to assess the safety and anti-tumor activity of these treatments when used together. After the tumor is surgically removed, patients will receive an injection of ipilimumab directly into the tumor site, along with nivolumab. Following this, nivolumab will be administered both into the cavity left by the tumor and through the vein. The study will monitor how the body responds to these treatments and any side effects that may occur.

Participants in the study will undergo regular check-ups and tests to track their progress. The study aims to gather information on how well these treatments work together in fighting glioblastoma and to ensure they are safe for patients. The trial will continue until the end of 2026, with the goal of improving treatment options for those affected by this aggressive form of brain cancer.

The purpose of the study is to determine if the combination of lomustine and reirradiation is more effective than using lomustine by itself for patients whose glioblastoma has returned after initial treatment. Participants in the study will be randomly assigned to receive either the combination treatment or lomustine alone. The study will monitor the participants over a period to assess their overall survival and other health outcomes.

Throughout the study, participants will undergo regular assessments to track the progress of their condition and any side effects they may experience. The trial aims to provide valuable information on whether adding reirradiation to lomustine treatment can offer better results for patients with recurrent glioblastoma.

The purpose of the study is to evaluate how effective and safe the combination of 2-OHOA with the standard treatment is for patients with glioblastoma. Participants in the study will be randomly assigned to receive either the new treatment combination or the standard treatment with a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are not biased.

Throughout the study, participants will receive their assigned treatment and will be monitored for changes in their condition. The study will look at how long patients live without the cancer getting worse, known as progression-free survival, and overall survival, which is the length of time patients live after starting the treatment. The study will also assess changes in neurological function and quality of life. The trial is expected to continue until enough data is collected to determine the effectiveness and safety of the new treatment approach.

The purpose of the study is to determine if adding lomustine to the standard treatment with temozolomide improves the overall survival of patients. Participants in the study will receive either the combination of temozolomide and lomustine or temozolomide alone, along with standard radiotherapy. The study will also explore whether the use of tumor treating fields provides any additional benefit. The treatment period can last up to 66 weeks, and participants will be monitored for their response to the treatment and any side effects they may experience.

Throughout the study, various aspects will be evaluated, including how long patients live after starting the treatment, how long they remain free from cancer progression, and their quality of life. The study will also assess the impact of the treatments on patients’ cognitive functions and any potential side effects related to the brain. The goal is to find out if the combination therapy offers a significant advantage over the standard treatment in terms of survival and overall well-being.

Participants in the study will receive the treatment through an infusion, which is a way of delivering medication directly into the bloodstream. The study will be conducted in different phases, starting with a dose-escalation phase to determine the safest and most effective dose of olaptesed pegol. Following this, there will be an expansion phase where more patients will receive the treatment to further assess its safety and effects. Throughout the study, patients will undergo regular monitoring, including MRI scans, to evaluate the treatment’s impact on the tumor and overall health.

The study aims to provide valuable information on the potential benefits and risks of using olaptesed pegol in combination with radiation therapy, and possibly with bevacizumab or pembrolizumab, for treating glioblastoma. This research could lead to new treatment options for patients with this challenging form of brain cancer. The study is expected to continue until the end of 2029, allowing researchers to gather comprehensive data on the long-term effects of the treatment.

The purpose of the study is to assess the safety and effectiveness of this combination of drugs. The study is divided into two phases. In the first phase, researchers will determine the best dose of ribociclib to use with the other medications. In the second phase, the study will further evaluate how well this combination works in treating neuroblastoma compared to a placebo. Participants will receive the medications either orally or through intravenous infusion, depending on the specific drug.

Throughout the study, participants will be closely monitored for any side effects and to see how their tumors respond to the treatment. The study aims to find the most effective and safe way to use these medications together to help treat these challenging cancers in young patients. The trial is expected to continue until 2029, allowing researchers to gather comprehensive data on the treatment’s impact.

The study is divided into two phases. In the first phase, the focus is on understanding the safety of meclofenamate sodium and finding the best dose to use. Participants will take the medication and be monitored for any side effects. In the second phase, the study will look at how well the combination of meclofenamate sodium and temozolomide works in treating glioblastoma. Participants will continue to take the medication and have regular check-ups to see how the treatment is affecting their cancer.

Throughout the study, participants will take the medications orally, meaning they will swallow the capsules. The study will last for several months, and participants will have regular visits with their healthcare team to monitor their health and the progress of their treatment. The goal is to find out if adding meclofenamate sodium to the standard treatment can help improve outcomes for people with glioblastoma.

The purpose of the study is to determine how safe and tolerable this new treatment is for patients with this type of glioblastoma. During the study, participants will receive the treatment and be monitored for any side effects or adverse reactions. The study will track the occurrence of any significant side effects within two weeks after the treatment is administered.

Participants in the study will be adults who have been newly diagnosed with this specific type of glioblastoma. The study will help researchers understand more about the potential benefits and risks of using PD L 506 in treating glioblastoma, which could lead to new treatment options for patients in the future.

Participants in the study will receive the treatment over a period of time, and their health will be monitored to assess the safety and tolerability of the treatment. The study will also look at how long patients live without the disease getting worse, which is known as progression-free survival. Additionally, the study will evaluate the quality of life and cognitive function of the participants, using specific questionnaires and tests designed to measure these aspects.

The study aims to gather information that could help improve treatment strategies for glioblastoma in the future. It will also explore the potential of using certain biological markers, called 4-miRNA signature-based risk subgroups, to better understand the disease and its progression. The study is expected to continue until 2027, with recruitment of participants starting in 2024.

The purpose of the study is to assess the safety and effectiveness of this combined treatment in patients who have had surgery for glioblastoma and are receiving standard radiochemotherapy. Participants in the study will receive the vaccine and temozolomide over a period of several months. The study will monitor how well the treatment works in preventing the cancer from getting worse and will also look at any side effects that may occur.

Throughout the study, participants will be closely observed to see how their bodies respond to the treatment. The researchers aim to understand if the combination of the vaccine and temozolomide can improve the chances of stopping the cancer from progressing and to evaluate the overall survival of the patients. This study hopes to provide valuable insights into new ways of treating glioblastoma and improving patient outcomes.

Participants in the study will be randomly assigned to receive either the early treatment with temozolomide or the standard treatment protocol. The study will begin treatment within 15 days after surgery or biopsy, which is earlier than the usual start time. The treatment will continue for a maximum period of 10 months. Throughout the study, participants will be monitored for their overall health and any side effects they may experience. The study aims to understand if the early use of temozolomide can lead to better outcomes for patients with glioblastoma.

Overall survival, which is the time from the start of the study until death from any cause, will be the main focus of the study. Additionally, the study will look at other factors such as the time until the disease progresses and the quality of life without symptoms or side effects. The study will also collect information on any adverse events, which are unwanted effects that may occur during the treatment. This information will help researchers understand the potential benefits and risks of starting temozolomide treatment earlier in patients with glioblastoma.

Participants in the study will receive either one of the experimental treatments or a placebo. The study will be conducted in two stages. In the first stage, the goal is to identify which treatments are most effective for different patient subtypes or based on specific biomarkers, which are unique characteristics found in the body. In the second stage, the study will confirm the effectiveness of these treatments to support the development of new medications.

The study will last for several weeks, with Troriluzole being administered for up to 48 weeks and ADI-PEG-20 for up to 104 weeks. Participants will be monitored regularly to assess their response to the treatment and any side effects. The main focus will be on overall survival, which means the time from starting the treatment until death from any cause. Other aspects, such as how long the disease stays stable or how the tumor responds to the treatment, will also be evaluated.

The purpose of the study is to compare the effectiveness of these treatments in improving the survival of patients with recurrent glioblastoma. Participants will undergo surgery to remove as much of the tumor as possible, followed by their assigned treatment. The study will monitor patients over a period of time to assess their overall survival and the progression of the disease. Patients will also be asked to report on their quality of life during the study.

Throughout the study, patients will receive regular check-ups and imaging tests, such as MRI scans, to track the size and growth of the tumor. The study aims to provide valuable information on which treatment approach may offer better outcomes for patients with this challenging condition. Participation in the study will involve regular visits to the clinic and adherence to the treatment plan as determined by the study protocol.

The purpose of the study is to explore how Perampanel affects the growth of the tumor and certain biological markers in the tumor tissue. Participants in the study will receive either Perampanel or a placebo before undergoing surgery to remove the tumor. The study will monitor changes in the tumor’s size and other characteristics using MRI scans, which are imaging tests that help visualize the inside of the body.

Throughout the study, participants will be closely observed to assess the impact of the treatment on their health and the tumor’s progression. The study aims to provide valuable insights into the potential benefits of Perampanel for patients with progressive glioblastoma, contributing to the development of more effective treatment strategies for this challenging condition.

Participants in the study will take the medications in the form of hard capsules, which are swallowed. The study will be conducted in two phases. In the first phase, researchers will determine the safest and most effective dose of NMS-03305293 when combined with temozolomide. In the second phase, the study will evaluate how well this combination works in shrinking the tumor or stopping its growth in patients with a specific type of glioblastoma known as IDH wild type.

Throughout the study, participants will have regular check-ups, including MRI scans, to monitor the tumor’s response to the treatment. The study will also assess the overall safety of the medication combination by tracking any side effects experienced by participants. The trial aims to provide valuable information on the potential benefits of combining NMS-03305293 with temozolomide for treating recurrent glioblastoma.

Participants in the study will receive either Debio 0123 with temozolomide or Debio 0123 with temozolomide and radiotherapy. The study will be conducted in phases, starting with a focus on safety and the best dose, and then moving on to evaluate how well the treatment works. Throughout the study, participants will be monitored for any side effects and changes in their health. The study will also look at how the medications are processed in the body, which is known as their pharmacokinetic profile. This includes measuring how much of the drug is in the blood at different times and how long it stays in the body.

The study is expected to continue for several years, with the goal of gathering enough information to determine if Debio 0123 can be a beneficial treatment option for people with glioblastoma. Participants will undergo regular health checks, including magnetic resonance imaging (MRI) scans, to monitor the progress of their condition and the effects of the treatment. The study will help researchers understand more about glioblastoma and potentially improve treatment options for this challenging disease.

The treatment involves taking Gliolan (the brand name for 5-Aminolevulinic acid) by mouth in combination with radiation therapy sessions. The main goal of this research is to determine the highest safe dose of the medication that can be given repeatedly during radiation therapy treatment without causing unacceptable side effects.

During the study, participants will receive different doses of the medication along with radiation therapy over a four-week period. The treatment schedule will be carefully monitored to evaluate how well patients tolerate the combination therapy and to assess any side effects that may occur. This includes monitoring for any effects on neurological function and skin reactions.

Participants in the study will undergo a process where their tumor cells are tested with various drugs to find the most effective treatment for their specific cancer. This approach is known as an Individualized Systems Medicine strategy. The study aims to determine if this method can successfully identify a treatment plan tailored to each patient’s unique cancer profile. The trial will also monitor the size of the tumor, any side effects from the treatments, and the overall survival of the patients involved.

The study will take place over a period of time, with the goal of completing by early 2026. During the trial, researchers will assess the ability to perform drug screenings and select possible treatment strategies based on the results. This innovative approach hopes to improve outcomes for patients with recurrent glioblastoma by providing more personalized and effective treatment options.

The purpose of the study is to see if this combination of treatments can help patients live longer without the cancer getting worse. Patients who participate in the study will receive these treatments over a period of time, and their health will be monitored regularly. The study will look at how long patients live without the cancer progressing, as well as their overall survival and response to the treatment. Safety will also be closely monitored, including any side effects that may occur.

Participants will take the medications by mouth, and the study will follow them for several years to gather information on the effectiveness and safety of the treatment. The study aims to provide new insights into treating glioblastoma and potentially improve outcomes for patients with this challenging condition.